U Clinical Progress Series Nonrheumatic Atrial Fibrillation
Risk of Stroke and Role of Antithrombotic Therapy John A. Cairns, MD, FRCPC, FACC, and Stuart J. Connolly, MD, FRCPC T here has been a long-standing consensus1 that the risk of embolization in patients with atrial fibrillation and rheumatic heart disease, in particular, mitral stenosis, is sufficiently high to justify anticoagulant prophylaxis. However, there has been no consensus in regard to nonrheumatic atrial fibrillation. The recognition that nonrheumatic atrial fibrillation is common and associated with a high risk of systemic embolization and stroke, as well as the suggestion of reduced embolism from both nonrandomized trials of oral anticoagulation in atrial fibrillation and randomized trials of anticoagulant and antiplatelet drugs in vascular diseases, heightened awareness of the potential efficacy of antithrombotic therapy. This recognition, together with evidence of the greater safety of lower-dose warfarin, prompted the initiation of several randomized trials of anticoagulant and antiplatelet therapy of nonrheumatic atrial fibrillation. Some of these trials are now complete, and a review of antithrombotic therapy in nonrheumatic atrial fibrillation is timely.
Many types of heart disease are associated with atrial fibrillation, including coronary artery disease, hypertension, congestive heart failure, and rheumatic heart disease. The incidence and outcome data from the Framingham Study2-6 distinguished rheumatic atrial fibrillation from atrial fibrillation unassociated with rheumatic heart disease. Most patients in recent studies of atrial fibrillation have had no evidence of rheumatic heart disease, and the term "nonrheumatic atrial fibrillation" has been widely adopted to describe the disorder in this group of patients.7-10 In a number of articles, the designation "nonvalvular atrial fibrillation" has been used synonymously with "nonrheumatic atrial fibrillation, "11 whereas strictly speaking it is not synonymous. All of the recent randomized clinical trials have focused on patients with atrial fibrillation unassociated with rheumatic heart disease, excluding rheumatic heart disease by the detection of echocardiographic mitral stenosis. Accordingly, some patients who were free of echocardiographic mitral stenosis but nevertheless had rheumatic atrial fibrillation have probably been enrolled and labeled as "nonrheumatic." Nevertheless, the term "nonrheumatic atrial fibrillation" probably describes the recent study populations better than the term "nonvalvular atrial fibrillation."
Prevalence and Incidence Epidemiological studies have reported wide variation in the prevalence of atrial fibrillation depending on the age and general health of the population studied; hence, it is necessary to obtain data from unselected or randomly selected populations. 11 .6% of those more than 75 years old. In their patients (60 years old or older), atrial fibrillation developed at an average rate of 0.5% per year. The increase in the prevalence of atrial fibrillation with age is associated with an increasing prevalence of coexisting heart disease; however, an independent direct effect of aging on atrial tissue cannot be excluded. 
Stroke
The risk of embolic stroke and other systemic embolism among patients with atrial fibrillation has long been recognized and attributed to left atrial enlargement and stasis and to mitral valve stenosis. Several cohort studies have reported the incidence of stroke among patients with atrial fibrillation and have clarified the relative risks among patients with rheumatic and nonrheumatic atrial fibrillation ( Table 3) . The Framingham Study3 demonstrated that among patients who developed chronic atrial fibrillation during 24 years of biennial follow-up, the risk of stroke (including transient ischemic attack) was markedly increased compared with those who did not develop atrial fibrillation. Patients were stratified according to the presence of rheumatic heart disease, and stroke risks were adjusted for age and blood pressure. The risk ratio for stroke was 17.56 for those with rheumatic atrial fibrillation and 5.6 for those with nonrheumatic atrial fibrillation; however, the absolute annual rate of stroke was virtually the same in the two groups, just more than 4%. In an analysis of the Framingham data after 30 years of follow-up6 including only nonrheumatic atrial fibrillation, the annual incidence of stroke was 3.8%; in comparison to controls matched for multiple risk factors, the relative risk was approximately 4.
Other cohort studies have found similar risks of stroke in patients with atrial fibrillation, although it is usually not possible in these studies to discern comparative rates among patients with and without rheumatic heart disease, as in the Framingham Study. For example, Roy et a123 reported an annual incidence of systemic emboli of 5.5% (70% were cerebral) in 254 patients with atrial fibrillation followed and not anticoagulated during 549 patient-years. The risk was similar for chronic and paroxysmal atrial fibrillation and for those with or without mitral valve disease.
The follow-up of the placebo groups in recently completed clinical trials provides current data on stroke incidence among patients with nonrheumatic atrial fibrillation. In the Copenhagen Atrial Fibrillation Trial (AFASAK) study,'0 among the 336 placebo patients, the annual incidence of stroke was 4.9% and of stroke plus transient ischemic attack was 5.8%. In the Stroke Prevention in Atrial Fibrillation (SPAF) study,24 among the 528 placebo patients, the annual incidence of stroke was 5.7% and of stroke plus transient ischemic attack was 7.8%.
The Framingham data6 allow an evaluation of the relative risk of stroke in relation to several risk factors, including nonrheumatic atrial fibrillation. In every decade from 50 to 79 years, cardiac failure, coronary artery disease, hypertension, and atrial fibrillation each made a significant independent contribution to the risk of stroke after the other risk factors were taken into account. However, in the decade of 80-89 years, only atrial fibrillation made a significant independent contribution. Of all of the 462 initially observed stroke events, atrial fibrillation Wiener et a130 reported that the only independent statistically significant predictor of systemic embolism was the chronicity of atrial fibrillation. Seventy-six percent of patients who had an embolic event had chronic atrial fibrillation compared with only 40% of those without embolism. Shimomura et a131 reported the incidence of systemic embolism among 572 consecutive patients from one cardiac center who had chronic or paroxysmal atrial fibrillation and were initially free of embolism. The rates of embolism per 1,000 patientyears were 15 for paroxysmal and 28 for chronic atrial fibrillation. An analysis of the Framingham data4 on patients with coronary heart disease showed that among men with chronic atrial fibrillation, the annual stroke rate was 5.4% and the relative risk was 4.7, whereas with transient atrial fibrillation, the annual stroke rate was only 1.3% and the relative risk was 0. In women, the annual stroke rate and relative risk of stroke were higher with chronic than with transient atrial fibrillation, but the differences were not so marked. In summary, although none of the studies alone is conclusive, the consistency with which paroxysmal atrial fibrillation is associated with a lower risk of stroke is compelling.
Lone atrial fibrillation. It is generally believed that the risk of stroke in lone atrial fibrillation is very low and may not be higher than that in a population of comparable age without atrial fibrillation. Evans and Swann19 reported no embolic events in their follow-up of 20 cases of lone atrial fibrillation. More recently, Kopecky et a120 reported a retrospective analysis of 97 patients less than 60 years old (mean age, 44 years) with lone fibrillation and without hypertension or insulin-dependent diabetes mellitus. The annual risk of systemic embolism was 0.55%, and it was similar for the paroxysmal and chronic groups. The small proportion (9%) of patients with chronic fibrillation and the relatively low mean age limit the generalizability of these data to all lone atrial fibrillation patients. Brand et a121 reviewed the Framingham data at the 30-year point of follow-up to determine the stroke risk of lone atrial fibrillation. Only 4.5% of the lone fibrillators were less than 50 years old, and 52% were 70 years old or older; cases were not excluded for hypertension or diabetes mellitus as they were in the study of Kopecky et al. 20 Atrial fibrillation was chronic in about half of patients. Lone fibrillation patients were compared with control patients free of atrial fibrillation and matched for a variety of risk factors. The age-adjusted rate of stroke was more than fourfold higher than in the control group, and the annual risk of stroke was about 2.5% per year. Most patients with a stroke had chronic atrial fibrillation. The discrepancy between this study and that from the Mayo Clinic is, at least in part, due to the great differences in age, cardiovascular risk factors, and chronicity of atrial fibrillation. Although one may have reasonable confidence of low risk in the younger patient with no cardiovascular risk factors and in whom the atrial fibrillation is paroxysmal, the risk of stroke for lone fibrillation may be substantial when the patient is elderly and the fibrillation is chronic.
Recent onset of atrial fibrillation. The Framingham data5 were used to investigate the antecedent duration of atrial fibrillation among patients with nonrheumatic atrial fibrillation who had sustained a stroke in the absence of other embolic source. In 14 of the 59 patients, atrial fibrillation was first diagnosed during initial hospitalization for stroke, and a total of 22 of 59 of all stroke victims (37%) had had atrial fibrillation for less than 2 years at the time of the first stroke. The actual incidence of stroke during different time periods is not discernible from the published data, although reports suggest a relatively high incidence during the first 2 years after the onset of nonrheumatic atrial fibrillation. In their study of paroxysmal atrial fibrillation and its progression to chronic atrial fibrillation, Petersen and Godtfredsen29 reported clustering of thromboembolic events both at the onset of paroxysmal atrial fibrillation and in the first year after progression to chronic atrial fibrillation. In persisting paroxysmal atrial fibrillation, the incidence of systemic embolism was 6.8% in the first month, decreasing to 2% per year thereafter. In patients progressing from paroxysmal to chronic atrial fibrillation, the rate of embolism was 13.3% in the first year and 4% per year thereafter. The risk of stroke appears to be higher in patients with recent onset atrial fibrillation than in those in whom atrial fibrillation has been present for more than 1-2 years.
Recent embolism. In atrial fibrillation patients who have had an embolic event, the risk of an early recurrence appears to be high. Hart et a132 reported a recurrence within 10 days in 13% of 23 nonanticoagulated patients with nonvalvular atrial fibrillation and previous stroke. The recurrence rate was 20% if events occurring as long as 11 days before the index stroke were included. Kelly et a133 reported a recurrence of stroke in 33% of 36 patients with atrial fibrillation during a mean follow-up of 2.5 months. The recurrence rate was 53% in the 19 nonanticoagulated patients. Darling et a134 reported the rate of recurrent thromboembolism within 14 days to be 19.6% in 148 patients with valvular and nonvalvular atrial fibrillation, and 49% of all recurrent emboli during the first 2 years occurred within the first 2 weeks after the initial embolic event. On the other hand, Sage and van Uitert35 reported the rate of recurrent embolism to be similar in the initial and later years after an initial stroke in 140 patients with nonvalvular atrial fibrillation. Some recent reports suggest that early recurrence rates are less marked36-38 than might be anticipated from an overview of earlier reports. Nevertheless, a rate of recurrent stroke in the range of 1-2% over the subsequent month is much higher than the overall rate of 5% per year among patients with nonrheumatic atrial fibrillation. There is a reasonably consistent pattern of an increased risk of recurrent embolism in the first few weeks after an initial embolic event.
Left atrial enlargement. Left atrial enlargement can be readily detected by echocardiography and has been evaluated as a predictor of stroke in atrial fibrillation. Some retrospective studies report that left atrial enlargement is predictive of stroke,39,40 whereas other retrospective30 and prospective41 studies fail to demonstrate such prediction.
Transthoracic echocardiography rarely detects left atrial thrombus in patients with nonvalvular atrial fibrillation and cerebral embolus. 42 Although the presence of atrial clot might suggest an increased risk of thromboembolism, definitive evidence is lacking. The left atrium and, in particular, the appendage are better visualized by transesophageal echocardiography, which may become a useful method of detecting left atrial thrombus and assigning risk for stroke.
Reducing Risk of Stroke Two basic strategies have evolved for reducing the risk of stroke in atrial fibrillation: cardioversion and antithrombotic therapy.
Cardioversion
Atrial fibrillation of recent onset often reverts spontaneously to sinus rhythm, and there is no evidence that cardioversion by electrical or pharmacological means reduces the risk of systemic embolism. Nevertheless, cardioversion is often undertaken in the expectation that in addition to a resolution of symptoms, the risk of embolization may be reduced. The rate of initial success in restoring sinus rhythm varies from 76% to 100%43,44; 25-81% of patients will remain in sinus rhythm during the next 6-12 months.43-46 By far the strongest and most consistent clinical predictor of sinus rhythm late after cardioversion is short duration of atrial fibrillation before cardioversion.4344 For example, Dittrich et a143 reported that if atrial fibrillation was present for less than 3 months, 67% were in sinus rhythm 6 months after cardioversion compared with 27% for those with atrial fibrillation of more than 3 months' duration. Although some investigators have reported left atrial size to predict long-term maintenance of sinus rhythm, the predictive power has been weak. 43 46 patients receiving quinidine were significantly more likely to remain in sinus rhythm during the year after cardioversion. However, the mortality rate was greater for those on quinidine than for those on placebo (2.7% versus 0.6%,p=0.05). Other class I agents are effective for maintenance of sinus rhythm, but the safety of this entire class of drugs has been put in question by the results of the Cardiac Arrhythmia Suppression Trial. 54 Thus, although there are theoretical benefits to cardioversion, the rate of maintenance of sinus rhythm is low without antiarrhythmic drugs, which may in turn be harmful.
Antithrombotic Therapy
Antiplatelet drugs. There are many drugs that inhibit platelet function by a variety of mechanisms,55 but in addition to aspirin, only sulfinpyrazone, dipyridamole, and ticlopidine are of clinical relevance. A recent meta-analysis of the antiplatelet drugs for the prevention of vascular disease has summarized the benefits of antiplatelet therapy in the secondary prevention of stroke, acute myocardial infarction, and unstable angina. 56 The observed reductions of a major vascular event (stroke, myocardial infarction, or vascular death) were 22% after stroke, 25% after myocardial infarction, and 36% after unstable angina; all were highly significant. Subgroup analysis showed no differences in efficacy among low-dose aspirin, high-dose aspirin, sulfinpyrazone, or the combination of aspirin and dipyridamole. A subsequent analysis by the Antiplatelet Trialists' Collaboration of the data from many additional trials has been consistent with the initial overview and, in addition, has demonstrated a beneficial effect of antiplatelet therapy in venous thromboembolism. Ticlopidine has been found to be effective in the prevention of stroke or death in patients with transient cerebral ischemia and may be of value in the treatment of unstable angina. 55 Aspirin is the antiplatelet agent of choice because of its efficacy, safety, simplicity of administration, and low cost. The unequivocal benefits of aspirin in the treatment of arterial vascular disease and the probable benefit in venous thromboembolic disease coupled with the relatively low toxicity prompted the assessment of its efficacy in several trials among patients with nonrheumatic atrial fibrillation. Anticoagulant Therapy Oral anticoagulation has been extensively demonstrated to be beneficial in the management of venous thrombosis and pulmonary embolism. 57 The potential benefits of early anticoagulation in acute myocardial infarction have been debated. However, the results from three major randomized trials58-60 and two overviews6162 provide unequivocal evidence of the benefits for the reduction of mortality, thromboembolism, and stroke.
The potential value of chronic anticoagulant therapy among survivors of myocardial infarction was assessed in a large number of trials, but equivocal results led to little enthusiasm for such therapy.
However, more recent data6364 provide impressive evidence for potential benefit of chronic oral anticoagulation for reduction in the risk of reinfarction, stroke, and death. The standard approach to the control of oral anticoagulation therapy is by measurement of prothrombin time prolongation. The initial recommendations for optimal prothrombin time prolongation to twofold to 2.5-fold that of control were based on measurements using human brain thromboplastin, which is a relatively weak stimulus to thrombin production.68 During the 1970s, most North American laboratories switched to the use of more potent thromboplastins, usually derived from rabbit brain.69 A given degree of depletion of coagulation factors by warfarin resulted in less prolongation of the prothrombin time ratio when the rabbit brain source rather than the human brain source of thromboplastin was used in the assay. It is likely that insufficient attention was given to this change of thromboplastin, and most physicians undertook to achieve prothrombin time ratios in the range previously recommended for the human brain preparation. These undertakings resulted in an increase in warfarin dosage and in a greater risk of hemorrhage. Recognition of these problems led to the definition of the international normalized ratio (INR) for the description of prothrombin time prolongation as a result of oral anticoagulant therapy. Use of this parameter takes into account the different thromboplastins that may be used in the measurement of prothrombin time and standardizes the observed result. Therefore, a constant INR will be obtained from the measurement of prothrombin time in a given blood sample using any available thromboplastin.
Review of earlier trials in acute myocardial infarction has confirmed that by North American standards of the early 1980s, relatively low-intensity anticoagulation was used; however, benefits were observed. Subsequently, trials have directly compared the different intensities of anticoagulation in venous thrombosis66 and bioprosthetic heart valves.67 Warfarin dose and bleeding were less with the lower-intensity anticoagulation, but antithrombotic efficacies were equal. The lower intensity of anticoagulation is now recommended for most thrombotic conditions,69 and the greater safety of low-intensity anticoagulation has been one of the stimuli to the initiation of the recent randomized trials of anticoagulant therapy in atrial fibrillation.
Clinical trials of antithrombotic therapy in atrial fibrillation-Nonrandomized trials. No properly controlled trials of anticoagulant therapy for the prevention of embolism in atrial fibrillation associated with mitral stenosis have been reported. Nevertheless, it is generally accepted that this therapy is effective, and none of the recent clinical trials evaluating anticoagulation in atrial fibrillation has included patients with mitral stenosis. The evidence supporting anticoagulation in rheumatic atrial fibrillation is weak, coming from nonrandomized studies using nonconcurrent control groups. Szekely70 found that the risk of recurrent embolism was 3.4% among 20 patients anticoagulated after an embolism compared with 9.6% among 46 patients not anticoagulated. Cosgriff71 reported 103 embolic episodes among 28 patients during 275 patient-months of follow-up before anticoagulation and 13 embolic episodes during 625 months after anticoagulation. Adams et a172 reported the rates of fatal embolism in 84 patients followed for a total of 209 patient-years. There were four fatal emboli among anticoagulated patients compared with 13 among the untreated group. Although these studies suggest a beneficial effect of anticoagulation, they are methodologically weak.
Bjerkelund and Orning73 compared anticoagulated and nonanticoagulated patients with atrial fibrillation or flutter during their hospital stay in Norway. Anticoagulant therapy was continued in patients already receiving it and was not instituted in those who were not already receiving it. All patients underwent at least one attempt at cardioversion, which was successful in approximately 80% of each group. Of the 437 patients, 228 were receiving anticoagulation, and 209 were not. Mitral stenosis was present in 52% of patients, 74% of whom were in the anticoagulant group. Eighty-two patients had had previous embolism, 82% of whom were in the anticoagulant group. Embolic events occurred in two (0.8%) anticoagulated patients and 11 (5.3%) nontreated patients (p=0.016).
Roy et a123 retrospectively analyzed the records of 254 patients with atrial fibrillation, 47% of whom had mitral valve disease, who were treated at one center over a mean of 3.3 years. The rates of embolism were similar for those with and without mitral valve disease and for those with paroxysmal and chronic atrial fibrillation. The annual rate of embolism for anticoagulated patients was 0.7% compared with 5.5% for those not anticoagulated (p<0.002).
Clinical trials of antithrombotic therapy in atrial fibrillation -Randomized trials. The Copenhagen AFASAK study10 was the first published randomized trial of antithrombotic therapy in nonvalvular atrial fibrillation (see Tables 4 and 5 for study comparisons). The study was performed at a single center, and patients were eligible if they had chronic atrial fibrillation. Exclusion criteria included rheumatic heart disease, risk factors for bleeding, and a requirement for anticoagulation. Patients were randomized to receive either warfarin (titrated to an INR of In a second analysis comparing all aspirin and placebo patients from groups 1 and 2, the event rates on aspirin and placebo were 3.2% and 6.3%, respectively, yielding a risk reduction of 49% (p=0.014). Post-hoc subgroup analysis of the aspirin/placebo comparison showed no difference in event rates among those more than 75 years old (7.4% annual rate in both groups) but a marked difference among those 75 years old or less (65% risk reduction).
The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)76 was a randomized, unblinded trial in patients with nonrheumatic atrial fibrillation among whom warfarin was compared with usual care (which included aspirin in 46% of patients). There were 420 patients randomized and followed for a mean of 2.2 years. The study was halted early when an interim analysis crossed the predetermined level of significance in favor of treatment. The outcome events were ischemic stroke and systemic embolism, and the primary analysis was based on the intention-to-treat principle. There were two events on warfarin and 13 on usual care; risk reduction was 86% (95% confidence intervals, 51% and 96%). There were two major bleeds on warfarin (including an intracranial hemorrhage) and one on usual care.
Although these three studies have used different constellations of outcome events, different doses of warfarin, and different types of analyses, they are remarkably consistent in regard to the estimate of the risk reduction seen with warfarin, which is more than 59% and statistically significant in all three studies ( Two of the studies also evaluated aspirin, with one reporting no effect and the other reporting a clinically important and statistically significant effect. Aspirin treatment in BAATAF was not randomized. To better compare the two studies that evaluated aspirin, we calculated approximate 95% confidence intervals of the risk reduction using published data from the studies. To make the comparison meaningful, both studies have been analyzed using the intention-to-treat principle, and only stroke and other systemic embolism have been included as events. As can be seen from Table 5 , the 95% confidence intervals of the estimates of risk reduction of aspirin of the two studies overlap, indicating that the results are, at least statistically, consistent with one another. The lower dose of aspirin (75 mg/day) used in AFASAK may explain the lesser observed efficacy. The mean age of the AFASAK patients was 74 years, considerably higher than that of the SPAF patients. It may be important that there was no benefit of aspirin apparent among patients more than 75 years old in the SPAF trial. The evidence for the efficacy of aspirin against stroke in atrial fibrillation is less compelling than the evidence supporting warfarin therapy; in our opinion, it is likely that aspirin is less effective than warfarin. Table 4 summarizes the main features of the randomized clinical trials that are completed or ongoing. It is expected that the results of these studies will confirm the benefit of warfarin, and a meta-analysis of the data may help to clarify whether there are subgroups of patients who are at particularly high or low risk of stroke or respond differently to warfarin. The second phase of the SPAF study is designed to determine whether warfarin and aspirin are equally potent, and the two ongoing European trials will also help to clarify the effectiveness of aspirin.
Although the benefit of long-term anticoagulant prophylaxis against stroke in patients with nonrheumatic atrial fibrillation is clear, there is some uncertainty as to the optimal anticoagulant management of the patient with atrial fibrillation at the time of onset of an acute embolic stroke. The relatively high risk of recurrent embolism is the motivation for early anticoagulation, but such therapy increases the risk of hemorrhagic transformation of the embolic brain infarction. The recommendations of the Cerebral Embolism Study Group for the early anticoagulant management of patients with cardioembolic stroke appear prudent. Based on their review of the literature and the results of the only randomized clinical trial, the group recommended anticoagulation of patients with small and moderate-sized embolic infarcts if a computed tomography scan performed 24 hours from stroke onset did not show hemorrhage. In patients with large infarction, it was recommended that anticoagulant therapy be delayed until the computed tomography scan was performed at 7 days to exclude delayed hemorrhage. 77, 78 Summary Observations and Recommendations Atrial fibrillation is rather rare in the young, but prevalence increases with age, reaching 3-5% after the age of 65 years. Congestive heart failure and rheumatic heart disease are potent independent risk factors for atrial fibrillation, whereas hypertension is less so, and coronary heart disease is not a consistent independent risk factor. All-cause mortality is doubled in patients with atrial fibrillation, and the annual incidence of stroke is 4-5% regardless of whether there is associated rheumatic heart disease. The relative risk of stroke is approximately 4 in patients with nonrheumatic atrial fibrillation, but it is much higher in those with rheumatic atrial fibrillation. These strokes often have severe consequences. The increased risks of death and stroke are consistently reported among patients with chronic atrial fibrillation associated with other evidence of cardiac disease; however, the risk appears to be significantly lower with lone or paroxysmal atrial fibrillation. Patients with a recent embolic episode appear to have a high risk of recurrence. No laboratory test has been developed that can predict those at high or low risk of stroke.
The efficacy of warfarin prophylaxis against stroke is apparent in three recently reported randomized clinical trials showing a more-than-59% reduction in the risk of stroke. Relatively conservative prolongation of prothrombin times was used, the rates of cerebral and other hemorrhage were low, and net patient benefit was clear in all completed trials. Aspirin was also evaluated in two of these studies; it was of no benefit in one but reduced stroke by 49% in the other. The true benefit of aspirin remains somewhat uncertain in that the overlapping confidence limits mean the observed results are not statistically inconsistent and the dose of aspirin may have been too low in the negative trial. There is no explanation of why elderly patients appeared to have no benefit even in the positive trial.
A physician may conclude from these results that the substantial risk of stroke associated with atrial fibrillation is reduced at least 59% by warfarin, whereas there is also a favorable trend in the reduction of vascular and all-cause mortality. With current regimens of anticoagulant dosage and monitoring, major bleeding is uncommon, and cerebral hemorrhage is very uncommon. Accordingly, the risk-tobenefit ratio clearly favors warfarin therapy, and most patients with atrial fibrillation would clearly benefit from its use.
However, the persisting risk of hemorrhage with even current regimens of warfarin therapy prompts careful evaluation of the possible benefit of aspirin, which is associated with very low hemorrhagic risk. The risk reduction for stroke with aspirin may be somewhat less than with warfarin, and the evidence is less definite. However, in the young patient with lone atrial fibrillation, in whom the stroke risk is very low, even a low risk of hemorrhage with warfarin therapy may be unjustified, and aspirin in a dose of 325 mg/day of the enteric-coated preparation appears to be a prudent alternative. The choice is less clear in the patient with paroxysmal atrial fibrillation; the young patient with minimal or no associated heart disease should probably receive aspirin, whereas the older patient should receive warfarin. Among patients at higher risk of hemorrhagic complications of warfarin, aspirin may be the preferable treatment; however, in the very elderly, a subgroup analysis suggests that aspirin may not be effective. The reports from ongoing clinical trials should clarify details about the relative risks and benefits of warfarin and aspirin in various subgroups of patients with atrial fibrillation.
